bluebird bio(BLUE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BLUE bluebird bio

Market Closed 04-04 16:00:00 EDT

4.95

+0.06

+1.23%

盘后4.95

+0.000.00%

19:48 EDT

High4.99	Low4.67	Vol218.89K
Open4.92	D1 Closing4.89	Amplitude6.54%
Mkt Cap48.46M	Tradable Cap48.13M	Total Shares9.79M
T/O1.06M	T/O Rate2.25%	Tradable Shares9.72M
P/B-1.54	ROE-295.35%	EPS-24.84
52wk High28.60	52wk Low3.56	P/E-0.20
Dividend0.00	Div.Yield0.00	ROA-31.00%

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"BLUE","market":"US","secType":"STK","nameCN":"bluebird bio","latestPrice":4.95,"timestamp":1743796800000,"preClose":4.89,"halted":0,"volume":218889,"hourTrading":{"tag":"盘后","latestPrice":4.95,"preClose":4.95,"latestTime":"19:48 EDT","volume":1122,"amount":5538.3552,"timestamp":1743810490732},"delay":0,"floatShares":9724238,"shares":9790070,"eps":-24.844152,"marketStatus":"Market Closed","change":0.06,"latestTime":"04-04 16:00:00 EDT","open":4.92,"high":4.99,"low":4.67,"amount":1062316.9979136,"amplitude":0.06544,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-24.844152,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1744012800000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1371614400000,"exchange":"NASDAQ","adjPreClose":4.89,"preHourTrading":{"tag":"盘前","latestPrice":4.84,"preClose":4.89,"latestTime":"09:29 EDT","volume":713,"amount":3426.11473,"timestamp":1743773373445},"postHourTrading":{"tag":"盘后","latestPrice":4.95,"preClose":4.95,"latestTime":"19:48 EDT","volume":1122,"amount":5538.3552,"timestamp":1743810490732},"volumeRatio":0.14322327952642191,"impliedVol":1.4174,"impliedVolPercentile":0.488},"requestUrl":"/m/hq/s/BLUE","defaultTab":"news","newsList":[{"id":"2524449342","title":"Biotech Stock Roundup: CORT Up on Study Data, Updates From AXSM, BMY, EXEL & More","url":"https://stock-news.laohu8.com/highlight/detail?id=2524449342","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524449342?lang=en_us&edition=full_marsco","pubTime":"2025-04-03 03:00","pubTimestamp":1743620400,"startTime":"0","endTime":"0","summary":"It was a busy week in the biotech sector, marked by significant regulatory and pipeline updates. Among these, shares of Corcept Therapeutics Incorporated CORT skyrocketed after a late-stage study met its primary goal. On the other hand, Axsome Therapeutics’ AXSM shares declined after announcing results from a study on major depressive disorder .Shares of Corcept Therapeutics Incorporated surged on March 31 after the company announced the success of the late-stage ROSELLA study.The phase III ROSELLA study evaluated its pipeline candidate, relacorilant, in combination with nab-paclitaxel for treating patients with platinum-resistant ovarian cancer.Axsome Therapeutics announced top-line data from the phase III PARADIGM study, which evaluated solriamfetol for the treatment of major depressive disorder  with and without severe excessive daytime sleepiness .Nonetheless, in the prespecified subgroup of patients with severe EDS, treatment with solriamfetol led to greater improvements in depres","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/biotech-stock-roundup-cort-study-190000499.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1868836591.USD","BLUE","EXEL","BK4007","BK4532","LU1571399168.USD","LU2242652126.USD","LU0306807586.USD","LU1074936037.SGD","LU1670710661.SGD","LU0321505439.SGD","LU1670710588.SGD","LU2360032135.SGD","LU1093756168.USD","LU0985481810.HKD","LU0882574055.USD","BMY","LU1989771016.USD","AXSM","BK4534","IE00BJT1NW94.SGD","LU2125154778.USD","LU0096364046.USD","LU0566484027.USD","BK4578","BK4556","LU1868836757.USD","LU0225284248.USD","BK4505","PFS","LU1585245621.USD","LU2125154935.USD","OS","LU1291159041.SGD","BK4588","CORT","LU0306806265.USD","LU1323610961.USD","LU1093756325.SGD","LU1670711123.USD","BK4585","LU1670711040.USD","IE00BSNM7G36.USD","IE00BJJMRZ35.SGD","LU2242646821.SGD","LU0321505868.SGD","LU1718418525.SGD","IE00B2B36J28.USD","LU0456855351.SGD","BK4097"],"gpt_icon":1},{"id":"2524467518","title":"BRIEF-Xcellbio Granted Bluebird Bio Commercial License, Got Into Supply Agreement For Use Of Co's Proprietary Cell Manufacturing Technology, Avatar","url":"https://stock-news.laohu8.com/highlight/detail?id=2524467518","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524467518?lang=en_us&edition=full_marsco","pubTime":"2025-04-02 20:03","pubTimestamp":1743595395,"startTime":"0","endTime":"0","summary":"BRIEF-Xcellbio Granted Bluebird Bio Commercial License, Got Into Supply Agreement For Use Of Co's Proprietary Cell Manufacturing Technology, AvatarApril 2 (Reuters) - bluebird bio Inc BLUE.O:XCELLBIO:","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250402:nFWN3QG0SP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4556","BK4578","BK4139","BLUE"],"gpt_icon":0},{"id":"2524467894","title":"Xcellbio: Granted bluebird bio Commercial License, Got Into Supply Agreement for Use of Co's Proprietary Cell Manufacturing Technology, Avatar","url":"https://stock-news.laohu8.com/highlight/detail?id=2524467894","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524467894?lang=en_us&edition=full_marsco","pubTime":"2025-04-02 20:02","pubTimestamp":1743595360,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250402:nFWN3QG0SP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4578","BK4556","BLUE","BK4139"],"gpt_icon":0},{"id":"2524047975","title":"BUZZ-U.S. STOCKS ON THE MOVE-Veritex, Gaming and Leisure Properties, Apple","url":"https://stock-news.laohu8.com/highlight/detail?id=2524047975","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524047975?lang=en_us&edition=full_marsco","pubTime":"2025-04-01 02:29","pubTimestamp":1743445744,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Veritex, Gaming and Leisure Properties, AppleMarch 31 (Reuters) - The S&P 500 and the Nasdaq declined on Monday, with technology stocks among the largest fallers, as inves","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nL3N3QE16T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HMST","LU0061475181.USD","NOVA","FLG","PG","SG9999015358.SGD","LU1674673428.USD","NVAX","COOP","AIG","NEM","ALNY","ELTX","SG9999014567.USD","SLDB","PINS","LU0820561818.USD","RKT","LPLA","TSHA","GLPI","BK4532","LU1145028129.USD","GT","FBK","VBTX","SRPT","GATE","ENZ","LITB","SSBK","PL","IIPR","IDYA","LYV","BLUE","TSYW.SI","ALSN","LU1674673691.USD","BK4017","LU0316494557.USD","BK4539","GSK.UK","LU2552382215.SGD","EBS"],"gpt_icon":1},{"id":"2523171925","title":"bluebird bio Is Maintained at Overweight by Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2523171925","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523171925?lang=en_us&edition=full_marsco","pubTime":"2025-03-31 22:53","pubTimestamp":1743432780,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BLUE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 31, 2025 10:53 ET (14:53 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BLUE"],"gpt_icon":0},{"id":"2523470619","title":"Bluebird Bio Shares Rise After Non-Binding Offer From Ayrmid","url":"https://stock-news.laohu8.com/highlight/detail?id=2523470619","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523470619?lang=en_us&edition=full_marsco","pubTime":"2025-03-31 21:52","pubTimestamp":1743429120,"startTime":"0","endTime":"0","summary":"Bluebird bio shares were 23% higher, at $5.03, after the company said it received an unsolicited, non-binding written acquisition proposal from Ayrmid.Ayrmid has offered to buy bluebird for an upfront cash payment of $4.50 a share and a one-time contingent value right of $6.84 a share, payable upon achievement of a net sales milestone, said Somerville, Mass.-based bluebird on Monday.On Feb. 21, bluebird agreed to be bought and taken private by funds managed by global investment firms Carlyle and SK Capital Partners for $3 a share in cash and a one-time contingent value right of $6.84 per share payable upon achievement of a net sales milestone.Bluebird previously engaged in discussions with Ayrmid as part of its comprehensive review of strategic alternatives, although Ayrmid didn't submit any proposal to bluebird as part of that process, bluebird said.Bluebird said its board of directors is reviewing the Ayrmid Proposal in consultation with its legal and financial advisors.The stock hit","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Bluebird Bio Shares Rise After Non-Binding Offer From Ayrmid","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4578","BK4556","BK4139","BLUE"],"gpt_icon":0},{"id":"2523439339","title":"BUZZ-U.S. STOCKS ON THE MOVE-Gene therapy cos, gold miners, chipmakers","url":"https://stock-news.laohu8.com/highlight/detail?id=2523439339","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523439339?lang=en_us&edition=full_marsco","pubTime":"2025-03-31 19:48","pubTimestamp":1743421708,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Gene therapy cos, gold miners, chipmakersEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call news","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nL6N3QE0ED:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVDY","2NVD.UK","NVD3.UK","SRPT","USAW.SI","SNVD.UK","NVDS","IIPR","LU0788108826.HKD","LU1066051225.USD","LU0203347892.USD","CRSP","NVDA","LU1732799900.SGD","NVIW.SI","TSHA","NVD","LU0511384066.AUD","X","NVDX","NVD2.UK","MACW.SI","AU","LU2756315664.SGD","BLUE","TSYW.SI","SG9999014567.USD","NEM","VRAX","3NVD.UK","NVDS.UK","LU0320765489.SGD","MRNA","SLDB","LU1720051017.SGD","LU2054465674.USD","NMAX","STLD","NVDD","NVDU","LU2290526834.HKD"],"gpt_icon":1},{"id":"2523159229","title":"BUZZ-Bluebird bio rises on non-binding bid for up to $110.5 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2523159229","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523159229?lang=en_us&edition=full_marsco","pubTime":"2025-03-31 17:58","pubTimestamp":1743415095,"startTime":"0","endTime":"0","summary":"BUZZ-Bluebird bio rises on non-binding bid for up to $110.5 million** Gene therapy maker Bluebird Bio's BLUE.O shares rise 10% to $4.49 premarket** BLUE said late on Friday it received a non-binding offer from privately held UK company Ayrmid for up to $110.5 million** Ayrmid offered to acquire bluebird for $4.50 per share upfront, totaling about $43.8 million, according to Reuters calculations** Ayrmid also offered an additional $6.84 per share, representing about $66.6 million, contingent upon bluebird achieving certain sales milestones** In February, BLUE said it had agreed to be taken private by Carlyle Group <CG.O> and SK Capital Partners, for $3 per share upfront along with the same $6.84 per share, contingent upon it achieving certain sales milestones** As of last close, BLUE has fallen 84% in the past 12 months","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nL6N3QE0DU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4135","BK4578","BLUE","CG","IE00BGHQF748.EUR","BK4139","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","BK4556"],"gpt_icon":0},{"id":"2523639566","title":"Bluebird bio receives non-binding bid for up to $110.5 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2523639566","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523639566?lang=en_us&edition=full_marsco","pubTime":"2025-03-29 05:39","pubTimestamp":1743197942,"startTime":"0","endTime":"0","summary":"Bluebird bio receives non-binding bid for up to $110.5 million March 28 (Reuters) - Gene therapy maker bluebird bio BLUE.O said on Friday it had received a non-binding offer from peer Ayrmid for up to","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250328:nL3N3QB1K5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4135","IE00BGHQF748.EUR","BK4556","CG","BLUE","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","BK4578"],"gpt_icon":0},{"id":"2523636606","title":"BUZZ-Bluebird Bio shares rally 11% in late trade on buyout offer","url":"https://stock-news.laohu8.com/highlight/detail?id=2523636606","media":"Reuters","labels":["shareholding","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523636606?lang=en_us&edition=full_marsco","pubTime":"2025-03-29 05:20","pubTimestamp":1743196812,"startTime":"0","endTime":"0","summary":"BUZZ-Bluebird Bio shares rally 11% in late trade on buyout offer** Shares in gene therapy co Bluebird Bio BLUE.O up 11% at $4.54 in after-the-bell trading after it confirmed receipt of unsolicited buy","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250328:nL2N3QB14J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4556","BK4578","BLUE","BK4139"],"gpt_icon":0},{"id":"2523635840","title":"Bluebird Bio Reviewing Competing Buyout Offer From Ayrmid for Up to $110.5 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2523635840","media":"Dow Jones","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523635840?lang=en_us&edition=full_marsco","pubTime":"2025-03-29 04:55","pubTimestamp":1743195300,"startTime":"0","endTime":"0","summary":"Bluebird Bio has received a competing bid from Ayrmid to buy the cash-strapped gene-therapy company in a deal potentially valued at up to $110.5 million.Bluebird said late Friday that Ayrmid made an unsolicited offer to buy the company in a cash-and-stock transaction with an upfront cash payment of $4.50 per share and a one-time contingent value right of $6.84 per share payable upon reaching a net sales milestone.The offer is about 10% higher than Bluebird's closing share price of $4.08 on Friday and a premium to a previous offer from two buyout firms that offered to pay $3 a share upfront for the company. The stock rose 10.5% in late trading to $4.51.Bluebird in February entered into an agreement with global investment firms Carlyle and SK Capital Partners to be acquired and taken private for up to $96 million in a mix of cash and shares. In addition to the $3 per share offer, the deal also proposed a one-time contingent value right payment of $6.84 a share, which would be payable upo","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4556","BK4578","BLUE"],"gpt_icon":0},{"id":"2523633753","title":"Bluebird Bio Gets Rival Buyout Proposal From Ayrmid; Shares Jump After Hours","url":"https://stock-news.laohu8.com/highlight/detail?id=2523633753","media":"MT Newswires Live","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523633753?lang=en_us&edition=full_marsco","pubTime":"2025-03-29 04:50","pubTimestamp":1743195005,"startTime":"0","endTime":"0","summary":"Bluebird bio  received an unsolicited, nonbinding buyout proposal from Ayrmid foran upfront cash payment of $4.50 a share and a one-time contingent value right of $6.84 a share, payable on reaching a net sales milestone.Bluebird had agreed to be acquired by funds managed by Carlyle  and SK Capital Partners for $3 a share in cash and a one-time contingent value right of $6.84 a share payable upon achieving a net sales milestone.Ayrmid didn't submit any proposal as part of the earlier review of alternatives, bluebird bio said Friday in a statement.Bluebird bio said it \"remains subject to the terms of the merger agreement\" with Carlyle and SK Capital, and the board \"has not changed its recommendation in support of the merger.\"The board is reviewing the Ayrmid offer, which is \"subject to certain conditions and further negotiations between the parties, including confirmatory diligence,\" blubird bio said.The shares of bluebird bio jumped 9.1% in recent after-hours trading.Price: 4.45, Change","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00B64PRP62.GBP","IE00BGHQF748.EUR","BK4135","BK4556","BLUE","BK4139","IE00B3QW5Z07.USD","CG","BK4578"],"gpt_icon":0},{"id":"2523663851","title":"BRIEF-Bluebird Bio Confirms Receipt Of An Unsolicited Non-Binding Proposal From Ayrmid","url":"https://stock-news.laohu8.com/highlight/detail?id=2523663851","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523663851?lang=en_us&edition=full_marsco","pubTime":"2025-03-29 04:24","pubTimestamp":1743193457,"startTime":"0","endTime":"0","summary":"BRIEF-Bluebird Bio Confirms Receipt Of An Unsolicited Non-Binding Proposal From AyrmidMarch 28 (Reuters) - bluebird bio Inc BLUE.O:BLUEBIRD BIO CONFIRMS RECEIPT OF AN UNSOLICITED NON-BINDING PROPOSAL ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250328:nTUA5QK0RN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4556","BLUE","BK4578"],"gpt_icon":0},{"id":"2523638810","title":"bluebird bio Inc Shares Gain Ground After the Bell Following Confirmation It Received Unsolicited Proposal, Last up 13% at Around $4.60","url":"https://stock-news.laohu8.com/highlight/detail?id=2523638810","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523638810?lang=en_us&edition=full_marsco","pubTime":"2025-03-29 04:21","pubTimestamp":1743193294,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250328:nL2N3QB11E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BLUE","BK4578","BK4556"],"gpt_icon":0},{"id":"2523633982","title":"Bluebird Bio confirms receipt non-binding proposal from Ayrmid","url":"https://stock-news.laohu8.com/highlight/detail?id=2523633982","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523633982?lang=en_us&edition=full_marsco","pubTime":"2025-03-29 04:20","pubTimestamp":1743193207,"startTime":"0","endTime":"0","summary":"bluebird bio (BLUE) confirmed it has received an unsolicited non-binding written proposal from Ayrmid Ltd to acquire bluebird for an upfront cash p...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bluebird-bio-confirms-receipt-non-binding-proposal-from-ayrmid?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bluebird-bio-confirms-receipt-non-binding-proposal-from-ayrmid?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4556","BK4139","BK4578","BLUE"],"gpt_icon":0},{"id":"2523807256","title":"bluebird bio Inc - Board Reviewing Ayrmid Proposal With Advisors","url":"https://stock-news.laohu8.com/highlight/detail?id=2523807256","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523807256?lang=en_us&edition=full_marsco","pubTime":"2025-03-29 04:15","pubTimestamp":1743192900,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250328:nTUA5QK0RN:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BLUE","BK4556","BK4139","BK4578"],"gpt_icon":0},{"id":"2523680728","title":"bluebird bio Inc  -  Ayrmid Did Not Submit Any Proposal to Bluebird as Part of Its Review of Strategic Alternatives","url":"https://stock-news.laohu8.com/highlight/detail?id=2523680728","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523680728?lang=en_us&edition=full_marsco","pubTime":"2025-03-29 04:15","pubTimestamp":1743192900,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250328:nTUA5QK0RN:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4578","BLUE","BK4556"],"gpt_icon":0},{"id":"2523680703","title":"bluebird bio Inc  -  Not Changed Its Recommendation in Support of Carlyle and SK Capital Partners Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2523680703","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523680703?lang=en_us&edition=full_marsco","pubTime":"2025-03-29 04:15","pubTimestamp":1743192900,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250328:nTUA5QK0RN:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4556","BK4578","BLUE"],"gpt_icon":0},{"id":"2523680408","title":"bluebird bio Confirms Receipt of an Unsolicited Non-Binding Proposal From Ayrmid","url":"https://stock-news.laohu8.com/highlight/detail?id=2523680408","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523680408?lang=en_us&edition=full_marsco","pubTime":"2025-03-29 04:15","pubTimestamp":1743192900,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250328:nTUA5QK0RN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4578","BK4139","BK4556","BLUE"],"gpt_icon":0},{"id":"2523807736","title":"Press Release: bluebird bio Confirms Receipt of an Unsolicited Non-Binding Proposal from Ayrmid","url":"https://stock-news.laohu8.com/highlight/detail?id=2523807736","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523807736?lang=en_us&edition=full_marsco","pubTime":"2025-03-29 04:15","pubTimestamp":1743192900,"startTime":"0","endTime":"0","summary":"bluebird bio, Inc.   today confirmed it has received an unsolicited non-binding written proposal  from Ayrmid Ltd  to acquire bluebird for an upfront cash payment of $4.50 per share and a one-time contingent value right of $6.84 per share payable upon achievement of a net sales milestone.Consistent with its fiduciary duties, the bluebird Board of Directors  is carefully reviewing the Ayrmid Proposal in consultation with its legal and financial advisors. bluebird remains subject to the terms of the Merger Agreement, and the Board has not changed its recommendation in support of the Merger. The Board will provide further updates to its stockholders as appropriate.Founded in 2010, bluebird has been setting the standard for gene therapy for more than a decade--first as a scientific pioneer and now as a commercial leader. bluebird has an unrivaled track record in bringing the promise of gene therapy out of clinical studies and into the real-world setting, having secured FDA approvals for th","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4578","BLUE","BK4556"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.bluebirdbio.com","stockEarnings":[{"period":"1week","weight":0.2132},{"period":"1month","weight":0.2375},{"period":"3month","weight":-0.4608},{"period":"6month","weight":-0.5658},{"period":"1year","weight":-0.7988},{"period":"ytd","weight":-0.4065}],"compareEarnings":[{"period":"1week","weight":-0.0907},{"period":"1month","weight":-0.1334},{"period":"3month","weight":-0.1464},{"period":"6month","weight":-0.1182},{"period":"1year","weight":-0.0152},{"period":"ytd","weight":-0.1379}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for curative severe genetic diseases in the United States. The company's product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. Its clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.022478},{"month":2,"riseRate":0.5,"avgChangeRate":-0.025518},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.073768},{"month":4,"riseRate":0.416667,"avgChangeRate":-0.009607},{"month":5,"riseRate":0.636364,"avgChangeRate":0.025424},{"month":6,"riseRate":0.545455,"avgChangeRate":0.106851},{"month":7,"riseRate":0.416667,"avgChangeRate":0.039553},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.046336},{"month":9,"riseRate":0.416667,"avgChangeRate":-0.031496},{"month":10,"riseRate":0.25,"avgChangeRate":-0.059779},{"month":11,"riseRate":0.5,"avgChangeRate":0.030416},{"month":12,"riseRate":0.5,"avgChangeRate":0.014064}],"exchange":"NASDAQ","name":"bluebird bio","nameEN":"bluebird bio"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"bluebird bio(BLUE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest bluebird bio(BLUE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"bluebird bio,BLUE,bluebird bio股票,bluebird bio股票老虎,bluebird bio股票老虎国际,bluebird bio行情,bluebird bio股票行情,bluebird bio股价,bluebird bio股市,bluebird bio股票价格,bluebird bio股票交易,bluebird bio股票购买,bluebird bio股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"bluebird bio(BLUE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest bluebird bio(BLUE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction